Rockefeller Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $88.6M | Sell |
467,619
-5,770
| -1% | -$1.09M | 0.14% | 142 |
|
|
2026
Q1 | $93.2M | Buy |
473,389
+146,169
| +45% | +$28.2M | 0.17% | 121 |
|
|
2025
Q4 | $60.2M | Sell |
327,220
-73,965
| -18% | -$13M | 0.11% | 176 |
|
|
2025
Q3 | $61.6M | Buy |
401,185
+31,343
| +8% | +$4.74M | 0.12% | 164 |
|
|
2025
Q2 | $51.7M | Buy |
369,842
+60,741
| +20% | +$8.51M | 0.11% | 179 |
|
|
2025
Q1 | $45.4M | Buy |
309,101
+110,492
| +56% | +$16M | 0.11% | 182 |
|
|
2024
Q4 | $26M | Buy |
198,609
+118,441
| +148% | +$16.6M | 0.07% | 276 |
|
|
2024
Q3 | $12.5M | Buy |
80,168
+1,370
| +2% | +$221K | 0.03% | 475 |
|
|
2024
Q2 | $12.3M | Buy |
78,798
+1,934
| +3% | +$291K | 0.03% | 447 |
|
|
2024
Q1 | $10.4M | Sell |
76,864
-10,122
| -12% | -$1.34M | 0.03% | 489 |
|
|
2023
Q4 | $11.7M | Sell |
86,986
-604
| -0.7% | -$78.5K | 0.04% | 410 |
|
|
2023
Q3 | $11.9M | Buy |
87,590
+1,037
| +1% | +$142K | 0.05% | 376 |
|
|
2023
Q2 | $12.4M | Buy |
86,553
+12,338
| +17% | +$1.82M | 0.05% | 378 |
|
|
2023
Q1 | $10.3M | Sell |
74,215
-2,095
| -3% | -$282K | 0.04% | 398 |
|
|
2022
Q4 | $10.3M | Buy |
76,310
+403
| +0.5% | +$50.5K | 0.05% | 350 |
|
|
2022
Q3 | $8.32M | Sell |
75,907
-6,233
| -8% | -$791K | 0.04% | 402 |
|
|
2022
Q2 | $10.9M | Buy |
82,140
+5,949
| +8% | +$781K | 0.06% | 324 |
|
|
2022
Q1 | $10.1M | Buy |
76,191
+33,472
| +78% | +$4.01M | 0.05% | 361 |
|
|
2021
Q4 | $4.98M | Sell |
42,719
-5,583
| -12% | -$657K | 0.02% | 541 |
|
|
2021
Q3 | $5.8M | Buy |
48,302
+22,176
| +85% | +$2.58M | 0.03% | 438 |
|
|
2021
Q2 | $3.13M | Buy |
26,126
+14,356
| +122% | +$1.58M | 0.02% | 600 |
|
|
2021
Q1 | $1.17M | Sell |
11,770
-1,195
| -9% | -$120K | 0.01% | 736 |
|
|
2020
Q4 | $1.29M | Buy |
12,965
+3,660
| +39% | +$388K | 0.01% | 628 |
|
|
2020
Q3 | $1.02M | Sell |
9,305
-454
| -5% | -$50.5K | 0.01% | 593 |
|
|
2020
Q2 | $1.03M | Buy |
9,759
+944
| +11% | +$97.5K | 0.01% | 544 |
|
|
2020
Q1 | $787K | Sell |
8,815
-6,074
| -41% | -$572K | 0.01% | 527 |
|
|
2019
Q4 | $1.49M | Buy |
14,889
+2,106
| +16% | +$198K | 0.02% | 389 |
|
|
2019
Q3 | $1.14M | Buy |
12,783
+2,651
| +26% | +$230K | 0.02% | 369 |
|
|
2019
Q2 | $836K | Sell |
10,132
-14,737
| -59% | -$1.16M | 0.01% | 365 |
|
|
2019
Q1 | $2.01M | Buy |
24,869
+24,481
| +6,310% | +$1.93M | 0.03% | 260 |
|
|
2018
Q4 | $29K | Buy |
+388
| New | +$30.3K | ﹤0.01% | 577 |
|
|
2018
Q3 | – | Sell |
-455
| Closed | -$32K | – | 755 |
|
|
2018
Q2 | $32K | Hold |
455
| – | – | ﹤0.01% | 485 |
|
|
2018
Q1 | $32K | Buy |
+455
| New | +$31.5K | ﹤0.01% | 441 |
|
Other funds holding AZN
EP
IA
Rockefeller Capital Management's AZN Position: Q2 2026 in Review
Rockefeller Capital Management reduced its AstraZeneca (AZN) stake by 1.2% in Q2 2026, selling an estimated $1.09M and leaving 467,619 shares worth $88.6M. The position accounts for 0.14% of the portfolio, ranked #142.
Rockefeller Capital Management first reported a position in AZN in Q1 2018 and has held it in 33 quarters since. The position peaked at $93.2M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Rockefeller Capital Management held 467,619 shares of AstraZeneca worth $88.6M as of Q2 2026.
- Rockefeller Capital Management sold 5,770 AstraZeneca shares in Q2 2026, an estimated $1.09M.
- AstraZeneca made up 0.14% of Rockefeller Capital Management's portfolio in Q2 2026, its #142 holding.
- Rockefeller Capital Management first reported a position in AstraZeneca in Q1 2018 and has held it in 33 quarters since.
- Rockefeller Capital Management's AstraZeneca position peaked at $93.2M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.